Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDEMA3: Evaluation of DX-88’s Effects in Mitigating Angioedema
2005-003819-71Phase 3Completed
- Sponsor
- Dyax Corp.
- Start
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of ecallantide in hereditary angioedema (HAE), sponsored by Dyax Corp. Primary endpoint: Treatment Outcome Score at 4 hours. Started Dec 2005; status: completed.
02
Drugs
ecallantide
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2005-003819-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003819-71.